

**WEST**

## Freeform Search

**Database:**

- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins**

**Term:**

**Display:**  **Documents in Display Format:**  CIT  Starting with Number

**Generate:**  Hit List  Hit Count  Image

---

---

### Search History

---

**Today's Date:** 11/5/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	uterotrophic and birth control (tectoridin or tectorigenin) and (dysmennorrhea or uterine bleeding or menopaus\$13 or hot flush or climacteric or osteо\$13 or cardio\$13 or angio\$11 or arter\$13 or athers\$13)	6	<u>L18</u>
USPT,PGPB,JPAB,EPAB,DWPI	Iridaceae and (dysmennorrhea or uterine bleeding) (l11 or l12 or l13) and (dysmennorrhea or uterine bleeding)	0	<u>L16</u>
JPAB,EPAB,DWPI	(l11 or l12 or l13) and (menopaus\$13 or hot flush or climacteric or osteо\$13 or cardio\$13 or angio\$11 or arter\$13 or athers\$13)	0	<u>L15</u>
JPAB,EPAB,DWPI	tectori\$11	16	<u>L13</u>
JPAB,EPAB,DWPI	tectoridin	1	<u>L12</u>
JPAB,EPAB,DWPI	tectorig\$7	8	<u>L11</u>
JPAB,EPAB,DWPI	(l7 or l8) and tectorig\$7	1	<u>L10</u>
JPAB,EPAB,DWPI	(l7 or l8) and tecotorig\$7	0	<u>L9</u>
JPAB,EPAB,DWPI	l7 and (menopaus\$5)	80	<u>L8</u>
JPAB,EPAB,DWPI	hot flush	127	<u>L7</u>
JPAB,EPAB,DWPI	testosterone same alpha\$1reducatase inhibitor	0	<u>L6</u>
JPAB,EPAB,DWPI	testosterone 5-alpha reducatase inhibitor	1	<u>L5</u>
USPT,JPAB,EPAB,DWPI	testosterone 5-alpha reducatase inhibitor	1	<u>L4</u>
USPT,JPAB,EPAB,DWPI	testosterone adj2 alpha reducatase inhibitor	1	<u>L3</u>
USPT,JPAB,EPAB,DWPI	testerone alpha reducatase inhibitor	0	<u>L2</u>
DWPI,USPT,EPAB,JPAB	testerone 5-alpha reducatase inhibitor	0	<u>L1</u>

**WEST****End of Result Set****Generate Collection**

L18: Entry 6 of 6

File: USPT

Sep 28, 1999

DOCUMENT-IDENTIFIER: US 5958916 A

TITLE: Dihydronaphthalene and naphthalene compounds,  
intermediates, formulations, and methods**BSPR:**

The present invention also provides methods for inhibiting estrogen deficient pathologies including, for example, lack of birth control, postmenopausal syndrome including, for example, osteoporosis, cardiovascular disease, restenosis, and hyperlipidemia, certain cancers in men such as prostate cancer, acne, hirsutism, dysfunctional uterine bleeding, dysmenorrhea, and atrophic vaginitis comprising administering to a mammal in need of treatment an effective amount of a compound of formula I, and, optionally, an effective amount of a progestin. One of skill in the art will recognize that estrogenic agents have a multitude of applications for treating estrogen deficient pathologies well beyond those listed infra. The present invention contemplates and encompasses such maladies although not specified by name.

**DEPR:**

The study would continue for six months, and each the patients would be examined for changes in the above parameters. During the course of treatment, the patients in the treatment group would show a decreased change in the biochemical markers of bone resorption as compared to the control group. Also, the treatment group would show little or no decrease in bone mineral density compared to the control group. Both groups would have similar uterine histology, indicating the compounds of formula I have little or no uterotrophic effects.